Avelumab

Generic Name
Avelumab
Brand Names
Bavencio
Drug Type
Biotech
Chemical Formula
-
CAS Number
1537032-82-8
Unique Ingredient Identifier
KXG2PJ551I
Background

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...

Indication

Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...

Associated Conditions
Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
Associated Therapies
First Line Chemotherapy, Maintenance therapy
Clinical Trials
Related News

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

First Posted Date
2021-05-04
Last Posted Date
2023-08-15
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
196
Registration Number
NCT04871529
Locations
🇺🇸

NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Illinois CancerCare-Eureka, Eureka, Illinois, United States

and more 89 locations

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

First Posted Date
2021-04-19
Last Posted Date
2024-06-10
Lead Sponsor
Emory University
Target Recruit Count
24
Registration Number
NCT04848519
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Phase 2
Recruiting
Conditions
Breast Cancer
Interventions
Drug: HCQ
Drug: Avelumab
Drug: Palbociclib
First Posted Date
2021-04-12
Last Posted Date
2024-03-12
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
96
Registration Number
NCT04841148
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 4 locations

A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

Active, not recruiting
Conditions
Urothelial Carcinoma
Interventions
Drug: Avelumab
First Posted Date
2021-03-30
Last Posted Date
2024-10-02
Lead Sponsor
Pfizer
Target Recruit Count
599
Registration Number
NCT04822350
Locations
🇫🇷

Centre Hospitalier Victor Dupouy, Argenteuil Cedex, France

🇫🇷

CHU Amiens-Picardie, Amiens Cedex 1, France

🇫🇷

Centre Hospitalier de la cote Basque, Bayonne, France

and more 78 locations

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

First Posted Date
2021-03-10
Last Posted Date
2024-10-21
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
18
Registration Number
NCT04792073
Locations
🇺🇸

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

🇺🇸

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 4 locations

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

First Posted Date
2021-01-08
Last Posted Date
2024-04-16
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
30
Registration Number
NCT04701918
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

First Posted Date
2021-01-06
Last Posted Date
2021-01-06
Lead Sponsor
Consorzio Oncotech
Target Recruit Count
75
Registration Number
NCT04698213
Locations
🇮🇹

ASL CN2 Alba-Bra, Alba, Italy

🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

🇮🇹

Irccs Istituto in Tecnologie Avanzate E Modelli Assistenziali in Oncologia Di Reggio Emilia, Reggio Emilia, Italy

and more 17 locations

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Completed
Conditions
Renal Cell Carcinoma
First Posted Date
2020-12-24
Last Posted Date
2022-09-16
Lead Sponsor
Pfizer
Target Recruit Count
481
Registration Number
NCT04682587
Locations
🇺🇸

Pfizer, New York, New York, United States

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

First Posted Date
2020-11-20
Last Posted Date
2024-07-31
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
3
Registration Number
NCT04637594
Locations
🇺🇸

CHI Health Saint Francis, Grand Island, Nebraska, United States

🇺🇸

CHI Health Good Samaritan, Kearney, Nebraska, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 374 locations

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

First Posted Date
2020-10-23
Last Posted Date
2023-08-08
Lead Sponsor
Genome & Company
Target Recruit Count
11
Registration Number
NCT04601402
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy